Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Global Automated Bioreactor Sampling Market is projected to grow at a CAGR of…
Key players in this market, are leading the innovation with advanced sampling solutions that integrate seamlessly into existing bioprocess workflows. These companies, are focusing on developing single-use and reusable systems that cater to different scales of production, from laboratory research to large-scale manufacturing. The introduction of more sophisticated analyzers, real-time monitoring capabilities, and integration with bioprocess control software is further enhancing the efficiency and…
PR Newswire
09/09/2024
Cardiac Tissue Engineering Market to Reach USD 1,333.6 M by 2029, Driven by Stem…
Browse in-depth TOC on "Cardiac Tissue Engineering Market" Browse in-depth TOC on "Cardiac Tissue Engineering Market" 426 - Tables 54 - Figures 336 - Pages Material Segmentation The market is divided into stem cells and scaffolds, with scaffolds further categorized into biological and synthetic types. In 2023, biological scaffolds held a significant market share due to their superior biological activity, which enhances cell adhesion and growth, and their ability to...
PR Newswire
09/09/2024
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 9 September 2024– On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under…
Nasdaq GlobeNewswire
09/09/2024
Novo Nordisk A/S - share repurchase programme
Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 9 September 2024– On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a…
Nasdaq GlobeNewswire
09/09/2024
Evaxion reports 69% Overall Response Rate in its phase 2 trial on lead cancer…
Topline data from a one-year interim analysis of the ongoing phase 2 trial show that 11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate 15 out of the 16 patients had reduction of their tumors (target lesions)The complete one-year dataset will be presented at the ESMO congress this week and discussed at a webinar with key opinion leaderProfessor Georgina V. Long on September 18, 2024 COPENHAGEN, Denmark, Sept.09, 2024(GLOBE NEWSWIRE)...
Nasdaq GlobeNewswire
09/09/2024
Aurora Cannabis and Vectura Fertin Pharma, Inc. announce launch of novel Luo CBD…
Launch represents Vectura Fertin Pharma's first medical cannabis CBD lozenge to be introduced in Canada Launch follows announcement of commercial collaboration between Cogent International, a Vectura Fertin Pharma subsidiary, and Aurora to leverage Aurora's Canadian medical cannabis patient platformCollaboration will explore the potential to launch Vectura Fertin Pharma's future medical cannabis portfolio in CanadaEdmonton, AB, and Stamford, CT – September 9, 2024- Aurora Cannabis Inc...
Nasdaq GlobeNewswire
09/09/2024
Chiesi Global Rare Diseases Launches New Research Grant Initiative to Support…
All applications will be independently reviewed and assessed by a Steering Committee of leading experts in the lysosomal storage disorders field, who have been identified, contracted and funded by Chiesi, with the successful applicants announced in Q1 2025. All applications will be independently reviewed and assessed by a Steering Committee of leading experts in the lysosomal storage disorders field, who have been identified, contracted and funded by Chiesi, with the successful applicants...
PR Newswire
09/09/2024
Tilray Medical Supports Scientific Study on Fibromyalgia With Positive Outcomes…
Tilray Medicaltitled, Treatment in Pain Management and Other Fibromyalgia-Associated Symptoms: A Case Series (TOMAS) . The study examines the real-world impact of cannabinoid treatments on patients with fibromyalgia (FM) under the guidance of healthcare providers. The TOMAS study, consisting of patients with an average age of 52 years, examined the effects of Tilray Dried Flower THC18 on chronic pain and other FM-associated symptoms. The study sheds light on the impact of...
Nasdaq GlobeNewswire
09/09/2024
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday…
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11ZUG, Switzerland,September 9, 2024 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, will host a Capital Markets Update for investors and analysts live from New York on Wednesday, September 11 from2024, from 9:00 – 10:30 EST/06:00 – 08:30 PST/14:00 – 16:30 CETThe event will...
Nasdaq GlobeNewswire
09/09/2024
Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine…
New pre-clinical data demonstrates that the novel EVX-B2 mRNA vaccine candidate triggers a targeted immune response The specific immune response leads to the elimination of the gonorrhea bacteriaThe data confirm that Evaxion's AI-Immunology™ platform is delivery modality agnostic COPENHAGEN, Denmark, Sept.09, 2024(GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines,...
Nasdaq GlobeNewswire
09/09/2024
Tineco's FLOOR ONE STRETCH S6 Receives Floor Cleaning Solutions Gold Award
Self-cleaning and flash drying by a press of the button The integrated FlashDry self-cleaning system ensures completely autonomous cleaning and drying of the brush roll and the entire vacuum cleaner at the push of a button. During self-cleaning, dirt particles are effectively removed from the brush roll and the pipeline by a heat flow of 70℃. During this process, the bi-directional brush rotates continuously to ensure a deeper and more thorough cleaning. This means the brush becomes particularly…
PR Newswire
09/09/2024
Buyback of Class B shares in Essity during week 36, 2024
The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. Class B shares in Essity were repurchased as follows: All purchases...
PR Newswire
09/09/2024
U-Ploid Announces Breakthrough Technology to Overcome Age-Related Infertility
"Our team is developing technology that directly targets the root cause of age-related female infertility," said Dr Chloe Charalambous, Co-founder & COO of U-Ploid Biotechnologies. "By improving the health of older eggs, we have the opportunity to help millions of people in their fertility journey." "Our team is developing technology that directly targets the root cause of age-related female infertility," said DrChloe Charalambous, Co-founder & COO of…
PR Newswire
09/09/2024
New bond financing agreement in a minimum amount of €3 million in anticipation…
Disclaimer: SAFE SA (the “Company”) has arranged financing in the form of convertible bonds into new or existing shares (OCEANE) with Global Corporate Finance Opportunities 20 (“GCFO 20”), which, after receiving the shares resulting from the conversion of these bonds, is not intended to remain a shareholder of the Company.The shares resulting from the conversion of these bonds will generally be sold on the market at very short notice, which may create strong downward pressure on the...
Nasdaq GlobeNewswire
09/09/2024
Trampoline Market to Reach $1.5 billion, Globally, by 2035 at 4.6% CAGR: Allied…
Prime determinants of growth Prime determinants of growth The trampoline market is expanding due to several important factors. The growing popularity of trampolines as an enjoyable form of physical exercise is a result of people's increased awareness of health and fitness, especially among children and adolescents. The popularity of trampoline parks along with the growth in sports and leisure activities has further stimulated market expansion. Trampolines have also become more...
PR Newswire
09/09/2024
Diamyd Medical to pursue accelerated approval pathway for Type 1 Diabetes…
Diamyd Medical recently announced Fast track designation in the U.S. for Diamyd®, and that the U.S. Food and Drug Administration (FDA) has acknowledged that accelerated approval could be sought based on a demonstration of significant treatment-related benefits on C-peptide levels, a measure of endogenous insulin production, in response to Diamyd® administration. The FDA's Accelerated approval program allows drugs for serious conditions that fills an unmet medical need to be approved based on a…
PR Newswire
09/09/2024
A. Menarini Diagnostics and Nucleix announce a strategic partnership for a…
This non-invasive CE-marked test detects primary or recurrent bladder cancer and upper tract urinary cancer. Bladder EpiCheck is included in the European Association of Urology (EAU) Clinical Guidelines as a urine test that might be used in the initial diagnostic workup of bladder cancer to avoid / implement cystoscopy and in follow-up to monitor for non-muscle invasive bladder cancer (NMIBC) tumor recurrence to replace or postpone cystoscopy. The test is also included in the EAU Clinical…
PR Newswire
09/09/2024
New insights highlight unmet needs for people living with Lennox-Gastaut…
These findings underline the need for new treatments that can target both drug-resistant seizures and the non-seizure symptoms of LGS. These findings underline the need for new treatments that can target both drug-resistant seizures and the non-seizure symptoms of LGS. DrKonrad Werhahn, Global Medical Affairs, UCB, said: "The impact of LGS goes beyond seizures and can include severe cognitive impairment, communication difficulties, psychiatric symptoms, behavioral challenges, and…
PR Newswire
09/09/2024
PolTREG Treg cell therapy for patients with type-1 diabetes shows long-term…
PTG-007 cell therapy resulted in clinical remission in some patients for up to 12 yearsA proportion of patients remained insulin-independent for up to 24 monthsPTG-007 ready to enter pivotal studyData presented at INNODIA EASD conferenceGdańsk, Poland – 9 September 2024– PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases, today announces data showing that treatment with its...
Nasdaq GlobeNewswire
09/09/2024
Roche advances AI-driven cancer diagnostics by expanding its digital pathology…
"We are excited to welcome these new collaborators into our digital pathology ecosystem," said Jill German, Head of Pathology Lab for Roche Diagnostics. "By combining our leadership in tissue diagnostics with a broad offering of state-of-the-art AI technology, we aim to revolutionise cancer research, diagnostics and treatment, ultimately helping clinicians improve the lives of patients worldwide." "We are excited to welcome these new collaborators into our digital…
PR Newswire
09/09/2024
Toshiba Unveils the High-End Masterstroke Series at IFA 2024, Showcasing a New…
As part of Toshiba's newest brand positioning, the Masterstroke Series redefines the role of home appliances in modern living. Moving beyond the mechanical and functional aspects, this series infuses a sense of humanity and high-end design, transforming everyday household items into artistic masterpieces. Embracing the philosophy of "LIFE AS THE BRUSH, HOME AS THE CANVAS," the series envisions living spaces as works of art, where each appliance enhances the aesthetic environment. As…
PR Newswire
09/09/2024
Ultimovacs Announces Updated Data Analysis on UV1 Phase II NIPU Trial in…
Oslo, September 9, 2024:Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces the presentation of updated data analysis from the UV1 Phase II NIPU trial (NCT04300244), at the 2024 ESMO Congress.The NIPU trial evaluated the addition of UV1 telomerase vaccine to immunotherapy with ipilimumab and nivolumab compared with ipilimumab and nivolumab alone, as a second-line treatment for patients...
Nasdaq GlobeNewswire
09/09/2024
Avacta to present updated clinical data on AVA6000 at the European Society for…
8 September 2024 Avacta Group plc (“Avacta” or “the Group” or “the Company”) Avacta to present updated clinical data on AVA6000 at the European Society for Medical Oncology (ESMO) CongressAvacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, today announces that the company will present updated data from the Phase 1a trial of AVA6000 at the 2024 European Society for Medical Oncology (ESMO) Congress,...
Nasdaq GlobeNewswire
09/09/2024
Lyophilized Reagent Beads Market Size to Grow USD 380 Million by 2030 at a CAGR…
Claim Your Free Sample Now: https://reports.valuates.com/request/sample/QYRE-Auto-28Z16292/Global_Lyophilized_Reagent_Beads_Market_Research_Report_2024 Claim Your Free Sample Now: https://reports.valuates.com/request/sample/QYRE-Auto-28Z16292/Global_Lyophilized_Reagent_Beads_Market_Research_Report_2024 Major Factors Driving the Growth of Lyophilized Reagent Beads Market: The market for lyophilized reagent beads is expanding as a result of the growing use of molecular diagnostics,...
PR Newswire
07/09/2024
Altri Comunicati